Ezetimibe is reserved for patients who do not achieve adequate lipid lowering or who are intolerant to statins, while PCSK9 inhibitors are strictly restricted to individuals with familial hypercholesterolemia or established cardiovascular disease who meet specific eligibility criteria. Here, PCSK9 is linked to familial hypercholesterolemia.